Xvivo Perfusion Ab Stock Beta
| XVIPF Stock | USD 23.52 0.00 0.00% |
As of the 17th of February 2026, Xvivo Perfusion maintains the Mean Deviation of 1.39, downside deviation of 3.38, and Market Risk Adjusted Performance of (6.73). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xvivo Perfusion AB, as well as the relationship between them. Please check out Xvivo Perfusion AB coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Xvivo Perfusion AB is priced fairly, providing market reflects its latest price of 23.52 per share. Given that Xvivo Perfusion AB has jensen alpha of 0.4835, we strongly advise you to confirm Xvivo Perfusion AB's prevalent market performance to make sure the company can sustain itself at a future point.
Xvivo Perfusion's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Xvivo Perfusion's valuation are provided below:Xvivo Perfusion AB does not presently have any fundamental gauges for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Xvivo |
Xvivo Perfusion 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xvivo Perfusion's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xvivo Perfusion.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Xvivo Perfusion on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Xvivo Perfusion AB or generate 0.0% return on investment in Xvivo Perfusion over 90 days. Xvivo Perfusion is related to or competes with Sanofi, CSL, GSK Plc, Fresenius, Sonova Holding, Essilor International, and EssilorLuxottica. Xvivo Perfusion AB , a medical technology company, develops solutions for organ, tissue, and cell preservation and perfu... More
Xvivo Perfusion Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xvivo Perfusion's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xvivo Perfusion AB upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.38 | |||
| Information Ratio | 0.1493 | |||
| Maximum Drawdown | 18.97 | |||
| Value At Risk | (1.38) | |||
| Potential Upside | 5.59 |
Xvivo Perfusion Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xvivo Perfusion's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xvivo Perfusion's standard deviation. In reality, there are many statistical measures that can use Xvivo Perfusion historical prices to predict the future Xvivo Perfusion's volatility.| Risk Adjusted Performance | 0.1477 | |||
| Jensen Alpha | 0.4835 | |||
| Total Risk Alpha | 0.2706 | |||
| Sortino Ratio | 0.1239 | |||
| Treynor Ratio | (6.74) |
Xvivo Perfusion February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1477 | |||
| Market Risk Adjusted Performance | (6.73) | |||
| Mean Deviation | 1.39 | |||
| Semi Deviation | 0.8408 | |||
| Downside Deviation | 3.38 | |||
| Coefficient Of Variation | 574.11 | |||
| Standard Deviation | 2.81 | |||
| Variance | 7.89 | |||
| Information Ratio | 0.1493 | |||
| Jensen Alpha | 0.4835 | |||
| Total Risk Alpha | 0.2706 | |||
| Sortino Ratio | 0.1239 | |||
| Treynor Ratio | (6.74) | |||
| Maximum Drawdown | 18.97 | |||
| Value At Risk | (1.38) | |||
| Potential Upside | 5.59 | |||
| Downside Variance | 11.45 | |||
| Semi Variance | 0.7069 | |||
| Expected Short fall | (6.23) | |||
| Skewness | 2.97 | |||
| Kurtosis | 12.72 |
Xvivo Perfusion AB Backtested Returns
Xvivo Perfusion appears to be not too volatile, given 3 months investment horizon. Xvivo Perfusion AB shows Sharpe Ratio of 0.18, which attests that the company had a 0.18 % return per unit of risk over the last 3 months. By examining Xvivo Perfusion's technical indicators, you can evaluate if the expected return of 0.53% is justified by implied risk. Please utilize Xvivo Perfusion's Mean Deviation of 1.39, market risk adjusted performance of (6.73), and Downside Deviation of 3.38 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Xvivo Perfusion holds a performance score of 14. The firm maintains a market beta of -0.0711, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Xvivo Perfusion are expected to decrease at a much lower rate. During the bear market, Xvivo Perfusion is likely to outperform the market. Please check Xvivo Perfusion's treynor ratio, as well as the relationship between the semi variance and day median price , to make a quick decision on whether Xvivo Perfusion's historical returns will revert.
Auto-correlation | 0.51 |
Modest predictability
Xvivo Perfusion AB has modest predictability. Overlapping area represents the amount of predictability between Xvivo Perfusion time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xvivo Perfusion AB price movement. The serial correlation of 0.51 indicates that about 51.0% of current Xvivo Perfusion price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 2.73 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Xvivo Perfusion AB has a Beta of 1.9656. This is 128.56% higher than that of the Healthcare sector and 89.0% higher than that of the Medical Devices industry. The beta for all United States stocks is notably lower than that of the firm.
Xvivo Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xvivo Perfusion's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Xvivo Perfusion could also be used in its relative valuation, which is a method of valuing Xvivo Perfusion by comparing valuation metrics of similar companies.Xvivo Perfusion is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Xvivo Perfusion will likely underperform.
Xvivo Fundamentals
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X | |||
| Revenue | 258.39 M | |||
| Gross Profit | 296.96 M | |||
| EBITDA | 39.2 M | |||
| Net Income | 8.15 M | |||
| Cash And Equivalents | 22.66 M | |||
| Cash Per Share | 0.86 X | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.48 X | |||
| Book Value Per Share | 2.28 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 133 | |||
| Beta | 1.97 | |||
| Market Capitalization | 674.8 M | |||
| Total Asset | 1.54 B | |||
| Net Asset | 1.54 B |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.